Toward Safe, Sustainable Chemical Synthesis: Iron-Catalyzed C-C and C-N Cross-Coupling
迈向安全、可持续的化学合成:铁催化的 C-C 和 C-N 交叉偶联
基本信息
- 批准号:9224997
- 负责人:
- 金额:$ 2.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-02-04 至 2017-06-03
- 项目状态:已结题
- 来源:
- 关键词:BehaviorBenignCarbonCatalysisChemicalsChemistryCollaborationsComplexConsumptionCouplingDataDependenceDevelopmentDiagnosisDiseaseDrug IndustryElectronsElementsExcisionGenerationsGoalsHealthHumanIn SituInstitutesInvestigationIronKnowledgeLigandsLongevityMetalsMethodologyMethodsNitrogenOxidation-ReductionPalladiumPharmaceutical PreparationsPharmacologic SubstancePlanet EarthPreparationProbabilityProblem SolvingProcessQuality of lifeReactionReagentResearchResidual stateResourcesTargeted ResearchTechniquesTechnologyTimeToxic effectWorkbasecatalystchemical synthesiscost effectivedesignexperimental studyhigh throughput screeninghuman diseaseinnovationnext generationnovelpreventpublic health relevancescreeningstemsuccesstool
项目摘要
DESCRIPTION (provided by applicant): The advent of pharmaceutical drugs that prevent, diagnose and treat disease has facilitated a revolution in human health. The discovery and manufacture of these substances rely on chemical transformations. It is crucial to render these processes as safe, sustainable and cost-effective as possible and to develop novel synthetic methods to enable discovery of new medications. Of currently available methods, palladium-catalyzed C-C and C-N cross coupling reactions constitute two of the most widely practiced strategies in the pharmaceutical industry. While offering efficient transformations using easily handled, available starting materials, prominent drawbacks stem from a reliance on palladium catalysts. Palladium is considered toxic, making the removal of residual metal after a cross-coupling step a significant issue in the pharmaceutical industry. Moreover, taking its natural scarcity and growing consumption into account, dependence on palladium is detrimental to the sustainability of these processes. In contrast, iron is the fourth most abundant element on Earth and is classified as a metal with no significant toxicity, making it an ideal choice for the pharmaceutical industry. Indeed, Fe-catalyzed cross coupling is a primary initiative of the ACS Green Chemistry Institute Pharmaceutical Roundtable and is the long-term goal of this research. Furthermore, this work presents the opportunity to discover new reactivity with iron not available to less abundant catalysts.
We have established a collaboration with the Catalysis Discovery Group of Bristol-Myers Squibb to develop Fe-catalyzed C-C and C-N cross coupling methodology. To be useful for pharmaceutical synthesis, these processes must incorporate stable carbon and nitrogen nucleophiles, reactivity that is currently unknown for iron catalysis. To overcome the considerable challenges associated with this transition, we will implement two parallel strategies - high throughput experimentation (HTE) and stoichiometric investigation. Rapid execution of considerable amounts of reactions enabled by HTE techniques will allow us to acquire extensive data regarding catalytic reactions in reasonable amounts of time. This information will be combined with fundamental knowledge gained in stoichiometric reactions of discrete, isolable iron complexes. A primary objective of the proposed research is the development of iron catalysts that engage in palladium-like behavior (two electron chemistry), efforts that will be facilitated by the preparation and observation of catalytically relevant iron complexes.
The research described herein presents an innovative approach to solving the challenges of practical Fe-catalyzed cross coupling by capitalizing on the unique advantages offered by two distinct strategies, therefore maximizing the probability for success. Targeting the incorporation of stable coupling partners distinguishes this research from current Fe-catalyzed cross coupling efforts and, more importantly, will contribute safe, sustainable processes for large-scale chemical synthesis.
描述(由适用提供):预防,诊断和治疗疾病的药物的进步已经准备了人类健康的革命。这些物质的发现和制造依赖于化学转化。至关重要的是,使这些过程尽可能安全,可持续和成本效益,并开发出新的合成方法来发现新药物。在当前可用的方法中,钯催化的C-C和C-N交叉耦合反应构成了制药行业中最广泛实践的两种策略。同时,使用易于处理的可用原材料进行有效的转换,但突出的缺点源于钯催化剂的缓解。钯被认为是有毒的,在交叉耦合步骤之后,将残留金属去除是制药行业的重大问题。此外,考虑到它的自然稀缺和不断增长的消费,对钯的依赖对这些过程的可持续性有害。相比之下,铁是地球上第四大元素,被归类为没有明显毒性的金属,使其成为制药行业的理想选择。实际上,Fe催化的交叉耦合是ACS绿色化学研究所制药圆桌会议的主要倡议,是这项研究的长期目标。此外,这项工作为发现新反应性的机会提供了一个机会,而铁无法获得较少的催化剂。
我们已经与Bristol-Myers Squibb的催化发现组建立了合作,以开发Fe催化的C-C和C-N交叉耦合方法。为了对药物合成有用,这些过程必须结合稳定的碳和氮核pholipses,这对于铁催化剂目前未知的反应性。为了克服与此过渡相关的考虑挑战,我们将实施两种平行策略 - 高通量实验(HTE)和化学计量研究。 HTE技术启用的反应量的快速执行将使我们能够在合理的时间内获取有关催化反应的大量数据。这些信息将与离散的,可隔离的铁配合物的化学计量反应中获得的基本知识相结合。拟议研究的主要目的是开发从事钯样行为(两种电子化学)的铁催化剂,这将通过制备和观察催化相关的铁配合物来制备。
此处描述的研究提出了一种创新的方法,可以通过利用两种不同的策略提供的独特优势来解决实用的Fe催化交叉耦合的挑战,从而最大程度地提高了成功的可能性。针对稳定耦合伙伴的就业,将这项研究与当前的FE催化交叉耦合工作区分开来,更重要的是,将为大型化学合成提供安全,可持续的过程。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Insight into Transmetalation Enables Cobalt-Catalyzed Suzuki-Miyaura Cross Coupling.
- DOI:10.1021/acscentsci.6b00283
- 发表时间:2016-12-28
- 期刊:
- 影响因子:18.2
- 作者:Neely, Jamie M.;Bezdek, Mate J.;Chirik, Paul J.
- 通讯作者:Chirik, Paul J.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jamie Marie Neely其他文献
Jamie Marie Neely的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
拷贝数突变致良性癫痫伴中央颞区棘波语言障碍的认知心理学及神经影 像学研究
- 批准号:82371201
- 批准年份:2023
- 资助金额:47 万元
- 项目类别:面上项目
LPA通过LPAR1和3亚型调控良性前列腺增生纤维样改变的机制研究
- 批准号:82370773
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
线粒膜融合蛋白Mfn1介导AR/Mfn1/PSA途径调控良性前列腺增生及植物源miR-5338靶向干预的研究
- 批准号:82374131
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
番茄红素对双酚A暴露相关良性前列腺增生的影响及免疫调控机制研究
- 批准号:82304142
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
I-Afadin调控三细胞间连接开闭在良性输尿管狭窄中的作用及其机制研究
- 批准号:82370691
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Biodegradable, Biocompatible Pressure Sensitive Adhesives
可生物降解、生物相容性压敏粘合剂
- 批准号:
10677869 - 财政年份:2022
- 资助金额:
$ 2.05万 - 项目类别:
Poly(glycerol carbonate) pressure sensitive adhesives for the in vivo closure of alveolar pleural fistulae
用于体内闭合肺泡胸膜瘘的聚(甘油碳酸酯)压敏粘合剂
- 批准号:
10746743 - 财政年份:2022
- 资助金额:
$ 2.05万 - 项目类别:
Biodegradable, Biocompatible Pressure Sensitive Adhesives
可生物降解、生物相容性压敏粘合剂
- 批准号:
10442908 - 财政年份:2022
- 资助金额:
$ 2.05万 - 项目类别:
Poly(glycerol carbonate) pressure sensitive adhesives for the in vivo closure of alveolar pleural fistulae
用于体内闭合肺泡胸膜瘘的聚(甘油碳酸酯)压敏粘合剂
- 批准号:
10463117 - 财政年份:2022
- 资助金额:
$ 2.05万 - 项目类别:
Multi-Level Optimization of Membrane Proteins for Crystallography
用于晶体学的膜蛋白的多级优化
- 批准号:
8307881 - 财政年份:2010
- 资助金额:
$ 2.05万 - 项目类别: